Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MicroRNA-299-3p as a potential marker of tumor size in non-small cell lung cancer.

Turk gogus kalp damar cerrahisi dergisi·2026
Same author

Sensitivity, Specificity, and Accuracy of Ultrasound, Mammography, and <sup>18</sup>F-FDG PET/CT in Diagnosing Breast Cancer Metastasis to Axillary Lymph Nodes: A Single-Center Experience.

Medicina (Kaunas, Lithuania)·2026
Same author

Integrating large-scale serum metabolomics and <i>APOE</i> ε4 genotype status for the non-invasive detection of Alzheimer's disease in the ADNI cohort.

medRxiv : the preprint server for health sciences·2026
Same author

Motivations for accepting or refusing Covid-19 vaccination in nursing homes and long-term care centers in France: the Vaccovid-senior study.

Geriatrie et psychologie neuropsychiatrie du vieillissement·2026
Same author

Long-Term Transcriptomic Reprogramming in Peripheral Blood Mononuclear Cells of Severe COVID-19 Survivors Reveals Pro-Oncogenic Signatures and Cancer-Associated Hub Genes.

Viruses·2025
Same author

Assessing the impact of sarcopenia on balance in the elderly: an analysis using a force platform.

BMC geriatrics·2025

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Dany Mukesha1,2, Maite Sarter1, Mélitine Dubray1

  • 1Firalis, Huningue, France.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

This study identifies key metabolomic biomarkers and APOE genotyping to differentiate Alzheimer's Disease (AD) from Dementia with Lewy Bodies (DLB). These findings may improve diagnostic accuracy for these overlapping neurodegenerative conditions.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neuroscience
  • Biochemistry
  • Computational Biology

Background:

  • Distinguishing Alzheimer's Disease (AD) from Dementia with Lewy Bodies (DLB) is clinically challenging due to overlapping symptoms.
  • Accurate differentiation is crucial for timely and appropriate patient management.
  • This study investigates novel biomarkers for improved differential diagnosis.

Purpose of the Study:

  • To identify distinct metabolomic profiles differentiating AD and DLB.
  • To evaluate the utility of machine learning models in classifying these conditions.
  • To assess the contribution of APOE genotyping to diagnostic accuracy.

Main Methods:

  • Serum samples from AD, DLB, and healthy control (HC) individuals were analyzed using targeted metabolomics (LC-HR-MS).
  • Machine learning algorithms (Lasso, Random Forest, XGBoost) were employed for classification.
  • APOE genotyping was integrated into the classification models.

Main Results:

  • Significant differences in APOE genotypes (e3/e4, e4/e4) were observed in AD patients compared to DLB and HC.
  • Lipid dysregulations, including phosphatidylcholines and sphingomyelins, were prevalent across groups.
  • The combination of 63 metabolites and APOE genotyping improved the Area Under the Curve (AUC) for AD vs. DLB classification from 0.78 to 0.81.

Conclusions:

  • Metabolomic biomarkers show promise in differentiating AD from DLB.
  • APOE genotyping enhances classification accuracy for AD.
  • Further validation in larger cohorts is needed to develop non-invasive diagnostic tools.